Cartesian Therapeutics (RNAC) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Cartesian Therapeutics (NASDAQ: RNAC):

• 6/10/2026 – Cartesian Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $38.00 price target on the stock.
• 6/9/2026 – Cartesian Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $40.00 price target on the stock.
• 6/9/2026 – Cartesian Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $44.00 price target on the stock.
• 5/27/2026 – Cartesian Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $38.00 price target on the stock.
• 5/26/2026 – Cartesian Therapeutics had its price target lowered by Needham & Company LLC from $42.00 to $40.00. They now have a “buy” rating on the stock.
• 5/12/2026 – Cartesian Therapeutics had its price target lowered by HC Wainwright from $30.00 to $25.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Cartesian Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $38.00 price target on the stock.

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.